A Phase Ib Trial of PX-12 Administered as a 72-Hour Infusion Every 21 Days in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer That is Refractory to Standard Treatment.

Trial Profile

A Phase Ib Trial of PX-12 Administered as a 72-Hour Infusion Every 21 Days in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer That is Refractory to Standard Treatment.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs PX 12 (Primary)
  • Indications Cancer metastases; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Feb 2010 Actual end date (Aug 2009) and actual number of patients (14) added as reported by ClinicalTrials.gov.
    • 11 Jun 2009 Status changed from active, no longer recruiting to completed. Final results have been presented.
    • 30 May 2009 Final results have been presented at American Society of Clinical Oncology (ASCO) Annual Meeting, according to an Oncothyreon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top